"
Optimal needle insertion length for intramuscular injection of risperidone long-acting injectable (RLAI)"
written by Tetsuya Tanioka, Sakiko Sakamaki, Yuko Yasuhara, Masahito Tomotake, Kensaku Takase, Chie Watari, Kouichi Makiguchi, Rozzano Locsin, Kazushi Motoki, Tatsuya Inui,
published by
Health,
Vol.5 No.12, 2013
has been cited by the following article(s):
|
[1]
|
Dorsogluteal intramuscular injection depth needed to reach muscle tissue according to body mass index and gender: A systematic review
Journal of Clinical Nursing,
2022
DOI:10.1111/jocn.16126
|
|
|
|
|
[2]
|
Evaluations of echogenicity in gluteal muscle in patients with schizophrenia treated with second generation long-acting injectable antipsychotics: risperidone or aripiprazole
Neurosonology,
2018
DOI:10.2301/neurosonology.31.7
|
|
|
|
|
[3]
|
Evaluations of muscle echogenicities in patients treated with second generation long acting injectable antipsychotics
Neurosonology,
2017
DOI:10.2301/neurosonology.30.13
|
|
|
|
|
[4]
|
Effects of Depth of Needle Insertion with Risperidone Long-Acting Injectable in Persons with Schizophrenia: A Randomized Double-Blind Study
Open Journal of Psychiatry,
2017
DOI:10.4236/ojpsych.2017.74031
|
|
|
|
|
[5]
|
Comparison of Gluteal Muscle Intramuscular Injection Sites of Japanese Healthy Subjects: Considerations for Optimal Insertion of Injection Needle Length
Open Journal of Psychiatry,
2016
DOI:10.4236/ojpsych.2016.62025
|
|
|
|
|
[6]
|
Intramuscular Diffusion Status of Risperidone and Aripiprazole Long Acting Injectable (LAI) by Ultrasonography
Open Journal of Psychiatry,
2016
DOI:10.4236/ojpsych.2016.62020
|
|
|
|